Survodutide has no approved label, so every dose figure here traces back to its published Phase 2 trials rather than a prescribing guideline. The obesity trial tested once-weekly subcutaneous doses of 0.6, 2.4, 3.6, and 4.8 mg, reached through a 20-week escalation followed by maintenance over 46 weeks total.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026Survodutide has no approved label, so these figures trace to its Phase 2 obesity trial, which escalated a once-weekly subcutaneous dose over 20 weeks before maintenance:
A separate Phase 2 MASH trial escalated further, testing 2.4, 4.8, and 6.0 mg weekly over 48 weeks. Because survodutide is still investigational, treat every number here as a description of what was studied, not a recommendation. Doses were stepped up gradually specifically to limit gastrointestinal side effects.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Survodutide is investigational. Talk to a doctor before starting any compound.